S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

NASDAQ:SLNO - Soleno Therapeutics Stock Price, Forecast & News

$1.54
+0.01 (+0.65 %)
(As of 12/5/2019 04:00 PM ET)
Today's Range
$1.53
Now: $1.54
$1.58
50-Day Range
$1.35
MA: $1.52
$1.73
52-Week Range
$1.11
Now: $1.54
$5.07
Volume91,600 shs
Average Volume463,449 shs
Market Capitalization$68.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 million
Book Value$0.96 per share

Profitability

Net Income$-13,340,000.00

Miscellaneous

Employees9
Market Cap$68.77 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.


Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Shares of Soleno Therapeutics reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.14. View Soleno Therapeutics' Earnings History.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Soleno Therapeutics.

What price target have analysts set for SLNO?

2 brokerages have issued 1-year price targets for Soleno Therapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they expect Soleno Therapeutics' share price to reach $7.50 in the next year. This suggests a possible upside of 387.0% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.

What is the consensus analysts' recommendation for Soleno Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.

Has Soleno Therapeutics been receiving favorable news coverage?

News articles about SLNO stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Soleno Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Soleno Therapeutics.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 40,200 shares, a decrease of 90.0% from the October 31st total of 401,300 shares. Based on an average daily volume of 42,100 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.2% of the shares of the company are short sold. View Soleno Therapeutics' Current Options Chain.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Molecular Templates (MTEM), Tetraphase Pharmaceuticals (TTPH), Opko Health (OPK), AVEO Pharmaceuticals (AVEO), Novavax (NVAX), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), Alibaba Group (BABA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the folowing people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Trellus Management Company LLC (0.93%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Edgar Engleman, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Institutional Ownership Trends for Soleno Therapeutics.

Which major investors are buying Soleno Therapeutics stock?

SLNO stock was acquired by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Edgar Engleman, Gwen A Melincoff, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $1.54.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $68.77 million and generates $1.45 million in revenue each year. The company earns $-13,340,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.View Additional Information About Soleno Therapeutics.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is http://www.soleno.life/.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]


MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: What is the CAC 40 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel